Subcortical volumetric alterations as potential predictors of methylphenidate treatment response in youth with attention-deficit/hyperactivity disorder

被引:4
|
作者
Kim, Ji-Sahn [1 ]
Lee, Kyung Hwa [2 ]
Hwang, Chan-Sop [1 ]
Kim, Jae-Won [2 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Med, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Psychiat, Seoul, South Korea
来源
JOURNAL OF PSYCHIATRY & NEUROSCIENCE | 2022年 / 47卷 / 01期
基金
新加坡国家研究基金会;
关键词
FUNCTIONAL CONNECTIVITY; TREATMENT-NAIVE; WORKING-MEMORY; ADHD; CHILDREN; HYPERACTIVITY; DEFICIT; DOPAMINE; SEGMENTATION; ADOLESCENTS;
D O I
10.1503/jpn.210074
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Patients with attention-deficit/hyperactivity disorder (ADHD) show structural alterations in the subcortical and dopaminergic regions of the brain. Methylphenidate is a first-line treatment for ADHD, and it is known to affect the subcortical and dopaminergic systems. The degree of pretreatment structural alterations in patients with ADHD may be an important factor in predicting methylphenidate treatment outcomes. The present study examined whether pretreatment volumetric alterations in the subcortical and dopaminergic regions predicted treatment response in youth with ADHD. Methods: This study included 67 youth with ADHD and 25 healthy controls. Youth with ADHD received 8 weeks of methylphenidate treatment. They completed baseline (pretreatment) T-1-weighted structural MRI scans and underwent clinical assessments before and after methylphenidate treatment. The healthy controls also completed baseline structural MRI scans. We assessed volumetric alterations using relative volumes (volume of each region of interest/intracranial volume). Results: Among 67 youth with ADHD, 44 were treatment responders and 23 were nonresponders based on post-treatment scores on the Clinical Global Impression Scale-Improvement. Nonresponders had larger volumes in the bilateral amygdala and right thalamus than responders. Nonresponders also had larger volumes in amygdalar subregions (i.e., the bilateral lateral nucleus and right basal nucleus) and hippocampal subregions (i.e., the right hippocampal head and right molecular layer) relative to responders. Limitations: We did not collect post-treatment structural T-1-weighted images, so volumetric changes related to methylphenidate treatment in youth with ADHD were undetermined. Conclusion: These findings suggest that pretreatment volumetric alterations in subcortical regions may serve as biomarkers for predicting methylphenidate treatment response in youth with ADHD.
引用
收藏
页码:E11 / E20
页数:10
相关论文
共 50 条
  • [41] A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder
    Martin A. Katzman
    Tia Sternat
    [J]. CNS Drugs, 2014, 28 : 1005 - 1033
  • [42] Mechanism of action of methylphenidate in treatment of attention-deficit/hyperactivity disorder - Introduction
    Markowitz, John S.
    Patrick, Kennerly S.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (03) : S37 - S38
  • [43] Parent cognitions as predictors of child treatment response in attention-deficit/hyperactivity disorder
    Hoza, B
    Owens, JS
    Pelham, WE
    Swanson, JM
    Conners, CK
    Hinshaw, SP
    Arnold, LE
    Kraemer, HC
    [J]. JOURNAL OF ABNORMAL CHILD PSYCHOLOGY, 2000, 28 (06) : 569 - 583
  • [44] Parent Cognitions as Predictors of Child Treatment Response in Attention-Deficit/Hyperactivity Disorder
    Betsy Hoza
    Julie Sarno Owens
    William E. Pelham
    James M. Swanson
    C. Keith Conners
    Stephen P. Hinshaw
    L. Eugene Arnold
    Helena C. Kraemer
    [J]. Journal of Abnormal Child Psychology, 2000, 28 : 569 - 583
  • [45] Assessment of Methylphenidate Prescriptions Written for the Treatment of Attention-Deficit/Hyperactivity Disorder
    Akici, Ahmet
    Gelal, Ayse
    Demircan, Dilek
    Tiskaoglu, Ramazan
    Topcus, Ibrahim
    Yilmaz, Huseyin
    [J]. KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 23 (01): : 42 - 48
  • [46] METHYLPHENIDATE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER IN BOYS WITH TOURETTES SYNDROME
    SVERD, J
    GADOW, KD
    PAOLICELLI, LM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1989, 28 (04): : 574 - 579
  • [47] A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder
    Katzman, Martin A.
    Sternat, Tia
    [J]. CNS DRUGS, 2014, 28 (11) : 1005 - 1033
  • [48] Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: A comparison with methylphenidate
    Fuchs, T
    Birbaumer, N
    Lutzenberger, W
    Gruzelier, JH
    Kaiser, J
    [J]. APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK, 2003, 28 (01) : 1 - 12
  • [49] METHYLPHENIDATE AND ATTRIBUTIONS IN BOYS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER
    PELHAM, WE
    VANNATTA, K
    GNAGY, EM
    LICHT, BG
    GREENSLADE, KE
    GREINER, AR
    MURPHY, DA
    MILICH, R
    VODDEHAMILTON, M
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1992, 60 (02) : 282 - 292
  • [50] Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
    Storebo, Ole J.
    Simonsen, Erik
    Gluud, Christian
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (18): : 2009 - 2010